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Abstract 
 
Chemokines play a significant role in attracting immune cells to extravasate to areas of 
peak expression in response to various stimuli. IL-8, MIP-1α and MIP-1β are known to be 
highly expressed in multiple cancers, as well as benign skin conditions. Their role in 
cutaneous Squamous Cell Carcinoma has yet to be established. 67 lesions suspicious for 
keratinocytic malignancy were sampled from 37 patients and tested for chemokine 
expression via Flow Cytometry. Each lesion was measured for thickness, histopathological 
grading, and immune cell infiltration score. Expression of the chemokines IL-8 and MIP-1α 
increased significantly with increasing lesion thickness (p = 0.0003***), histopathological 
grading (p = <0.0003***), and infiltration score (p = <0.01***). These data demonstrate the 
increase in proinflammatory chemokines with tumour progression which has not previously 
been described in cutaneous Squamous Cell Carcinoma.  
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Introduction 
 
While it is recognized that skin and particularly Squamous Cell Carcinoma (SCC) is highly 
infiltrated by immune cells, there remains conflicting data regarding the presence and 
relative significance of different immune cell subtypes. The changes in both tumour and 
peritumoral stroma that occur affect and are affected by chemical signals attracting 
different cells to the area. Extensive research has investigated the presence of, and 
prognosis associated with immune cell subsets existing in cutaneous disease and 
malignancy. Chemotactic cytokines (Chemokines) provide expression dependent signaling 
to induce migration of receptor positive immune cells (Chemotaxis). The presence of 
chemokines can be both a cause and consequence of the immune cell microenvironment 
of tumours, and can influence tumour rejection as well as progression and survival. This is 
generally thought to be due to epigenetic changes relating to apoptotic proteins, with 
propagation of tumour growth and metastatic potential via angiogenic and lymphaniogenic 
stimulation. 
 
To date, very little data exists on the qualitative and quantitative nature of chemotactic 
cytokine (Chemokine) expression in cutaneous squamous cell carcinomas. The significant 
prognostic data relating to chemokine expression in Head/Neck SCC, melanoma, ovarian 
and pancreatic cancers warrants further research into their role in cutaneous SCC (cSCC).  
 
This study aims to quantify the presence of chemokines in squamous cell carcinoma, by 
proposing the hypothesis: 
 
The expression of IL-8, MIP-1α and MIP-1β increase with increasing tumour thickness of 
squamous cell carcinoma and its precursor lesions.  
 
This data will be correlated with tumour thickness, the degree of immune cell infiltration, 
and histopathological subtype.  
 
To achieve this, a broad review of the available and relevant literature was performed, with 
particular focus on the role of chemokines in the skin, and their significance in other 
human cancers.  
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Theoretical Foundation  
The significance of chemokine over-expression correlating with worsening prognosis in 
other human cancers has been well established. Studies investigating the presence of IL-8 
in melanoma; ovarian and pancreatic cancer cell lines demonstrate hypoxic induction in 
response to ischaemic conditions. Over-expression has been correlated with increased 
angiogenesis of new vessels, and blockade of IL-8 receptors reduces tumorigenicity, and 
improves tumour clearance1,2. The C-C Chemokines CCL3/CCL4 are over expressed by 
Myeloid-Derived Suppressor Cells (MDSCs) in lymphoma, and act to attract Reguatory T 
Cells (T-Reg) infiltration, a factor associated with worse prognosis in cSCC. A reduction in 
the CCR5 receptor for CCL3/CCL4 reduces T-Reg infiltration in murine models and would 
theoretically predict an improved prognosis3,4.  
Nature of the study 
This study utilized samples from random patients with lesions clinically diagnosed as 
keratinocytic cancers suspicious for cSCC. Fundamental independent differences between 
patients were location of lesion, lesion thickness, histopathological grading, inflammatory 
cell infiltration. The dependent variable of chemokine expression was evaluated and 
analyzed for univariate relationship to the independent variables.  
Assumptions 
Patients were questioned in regard to their general health and in particular, any 
immunosuppressive conditions or medications that may impact on the outcomes of the 
study. No patients were taking immunosuppressant medications (although no data was 
collected on other medications), and it was assumed that any general medical 
comorbidities (Diabetes, Peripheral Vascular Disease) significantly impacted on immune 
behavior, as any significant comorbidities would preclude surgery.  
 
Scope and Delimitations 
The patients and skin lesions studied represent the majority of patients with cSCC disease 
across Australia. Patients were of the at risk age group (50+yrs old) for Non-Melanoma 
Skin Cancer (NMSC) (age was not limited), and had no major systemic disease that would 
have precluded surgical resection of these cancers. Although the plastic surgeon works in 
private practice, most patients were funded by DVA repatriation benefits and therefore 
socioeconomic disparity was not deemed significant.  
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Whilst skin types ranged from Fitzpatrick I-IV, the majority of patients displayed Type I-II 
skin, representing the highest risk population for NMSC. Gender bias was not examined 
nor controlled for, and the population represented a random sampling of patients in 
attendance for surgery. 
Limitations 
This study examined a random population presenting for care from a plastic surgeon, in a 
secondary referral process from general practitioners. The lack of adequate numbers of 
control (normal skin) samples from each patient, as well as examinable (abnormal, 
immunosuppressed) subjects limited the internal validity of the study. Being unable to 
provide a normal sample for each patient reduced the impact of quantification for each 
lesion, particularly in advanced disease where variance between samples was high. 
Although flow cytometry was repeated in duplicate for each sample, and the test repeated 
3 different times with separate kits, the study lacked a secondary validation model to 
ensure external validity and reproducibility in quantifying chemokine expression.  
Significance of Study 
This study fills a gap in the scientific literature regarding the expression of chemokines in 
the skin throughout the development of cutaneous squamous cell carcinoma. This follows 
on from studies in other cancers such as Melanoma, Ovarian and Pancreatic Cancer, 
demonstrating the significance of IL-8, MIP-1α and MIP-1β in disease progression and 
worsening prognoses.  
 
The results of this study will not directly influence change in clinical care. However, it does 
highlight the role of the clinician scientist in facilitating the link between clinical care and 
laboratory based research in human subjects, further demonstrating the potential for future 
collaborative endeavours.   
Summary  
This is a quantitative study, which answers the question “does chemokine expression 
correlate with increasing tumour thickness in cutaneous squamous cell carcinoma”. This 
bridges a gap in the medical literature surrounding the behavior of the skin in response to 
increasing dysplastic keratinocytic burden and the inflammatory response to cancer.  
The results of this study provide a quantitative measure of chemokine expression from 
normal skin through its dysplastic changes to invasive cSCC. Whilst this does not provide 
a qualitative measure of the cell types present in response to these conditions, it does give 
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an indication of the degree of inflammatory response present and correlates this with the 
thickness of each lesion.  
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Review of the Literature 
 
Skin cancer is the most common malignancy in the world, accounting for 1 in every 3 
cancers diagnosed5. The majority (96%) of these are Non-Melanoma Skin Cancers 
(NMSC), predominantly made up of Basal Cell Carcinomas (BCC) and Squamous Cell 
Carcinomas (SCC)6. Current estimates suggest treatments for NMSC across Australia 
have increased from 412,493 in 1997 to 767,347 in 2010 and are estimated to continue to 
increase. These figures accompany a significant financial imposition, estimated at $511 
million per year and expected to rise to $1 billion AUD by the turn of the decade7. 
 
Despite public awareness campaigns leading to an increased public vigilance and lower 
threshold to seek treatment at earlier stages, the delay in diagnosis and late stage 
presentations force more invasive treatment and increase both patient morbidity and 
financial cost to the health system. 
 
Of the NMSCs, lesions classified as SCC are believed to exist on a spectrum of disease 
from early, easily treatable scaly lesions, to large fungating tumours requiring complex and 
morbid surgical procedures to resect. The vast majority of these early stage lesions are 
rejected by the body’s immune system, and only a small number progress to invasive 
disease8. This capacity for host defense is reversed in immunosuppressed patients, 
suggesting a significant role for the immune system in both tumour surveillance and 
rejection. Further research into the role of the immune system and its response to both 
early and late stage lesions is required to facilitate the development of treatments that 
could potentially assist the body in rejecting these cancers.  
Histopathology of Squamous Cell Carcinoma 
Non-Melanoma Skin Cancer is a broad based term referring to multiple subtypes of cancer 
that are primarily induced by UV radiation damage from excessive sunlight exposure. 
BCCs are the most common form of NMSC, and develop at a rate of 3.7:1 when compared 
to SCCs9. These tumors grow slowly, invade locally and very rarely metastasize to other 
areas.  
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Figure 1. Annual risk of AK or multiple AK progressing to form cSCC or metastatic disease. Figure from Ratushny et al, 
20128,10–12 
 
SCCs are clinically and histopathologically distinct – being formed largely by progression 
from smaller lesions and deteriorating with further damage into more aggressive and 
morbid tumours capable of metastasis. Risk factors for NMSC are commonly excess sun 
exposure in individuals with fair skin that burns easily. Differences in the molecular 
pathogenesis of NMSC is evident in immunosuppressed patients, where the ratio of 
BCC:SCC is reversed to 1:2, and the risk of SCC increases 60-100 fold9.  
 
 
 
Figure 2. Stylised representation of theory of chemokine expression during SCC development. Chemokine expression 
changes in the small numbers (0.5-1.5%) that progress to more invasive disease. *Data from Rigel et al., 201313 
 
 
SCCs form on a spectrum of disease from early hypertrophic lesions such as Actinic 
Keratosis through to invasive cancers. Epidemiologic studies suggest only 0.5-1% of AK 
go on to form SCC, but between 40-60% of SCC are thought to have formed progressively 
from AK lesions. Clinically a large number of such lesions are treated without regard for 
tissue diagnosis by general practitioners in the community which may skew available 
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recorded data, however this still leaves a significant number of AK that are rejected by the 
patients immune response.  
 
Significant changes in the phenotype of the immune microenvironment occur during this 
malignant transformation, and despite countless studies into genetic and structural 
makeup, there has been a paucity of research into the signaling proteins that facilitate 
these changes. Chemotactic cytokines (Chemokines) provide expression dependent 
signaling to induce migration of receptor positive immune cells (Chemotaxis).  
 
As dysplasia and cellular proliferation continues, it is plausible that expression of such 
proteins would alter and potentially increase with increases in cellular load – resulting in a 
cellular microenvironment, which would vary accordingly from other lesions along the 
spectrum.  
 
Inflammatory Infiltration of Cancer 
Infiltration of inflammatory immune cells as a result of chemotactic protein expression can 
influence dysplastic change in skin cells and drive malignant transformation14. Cellular 
inflammation results from multiple causes (microbial invasion; trauma; hypoxia; chemical 
irritation; genetic mutations) and can be either acute or chronic or a continuum of both, 
and following observations of malignancy arising from sites of chronic inflammation, is now 
thought to be a pre-requisite, rather than a consequence, of malignancy15.  The prognostic 
significance of immune cell infiltration has been extensively studied in Colorectal Cancer 
and Melanoma and, whilst controversial, remains at the forefront of cancer research 
directed towards targeted therapies16–18. 
 
The immune system is heavily active in the skin, eliciting responses to microbial stimuli, 
trauma, and dysplastic change. Dendritic cells monitor for tumour antigens that are later 
presented via lymph drainage, to T and B lymphocytes19. 
 
Antigen presenting cells provide oncogenic stimulus for cytotoxic cells to extravasate: The 
production of CCL2/CCL3 by NK cells stimulates DCs to express CXCL9/CXCL10 and, in 
turn, attract CD8+ T Cells20. This effect appears to rely upon proximity to the tumour core 
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in cSCC, DCs from peritumoral skin were stronger stimulators of T-Cell proliferation 
compared to those more centrally located21 
  
The effective response of immune cell infiltration is reduced in invasive cSCC, and they 
are capable of evading the effective immune response through multiple mechanisms22. 
Immune infiltration relies on gradient driven expression of chemotactic proteins and 
vascular extravasation for effect.  
The prognostic significance of T-Cell infiltration is a source of contention that varies based 
on the tumour type. Infiltration of T-Regs is associated with better outcomes and overall 
longer survival in Colorectal Cancer17,18,23. This effect is reversed or not present in most 
other cancers, including cSCC, where their presence is associated with a worse prognosis. 
The presence of high intratumoral NK, and cytotoxic Th1 infiltration is associated with a 
favourable prognosis in the majority of human cancers19. 
 
Over 50% of T-Cell infiltrates in untreated cSCC are FOXP3+ T-Regs, and display minimal 
Ki-67 staining, suggesting migration and not local division in response to inflammatory 
stimuli24.  Tumour cells act to reduce E-selectin expression, and prevent CLA+ T Cell 
extravasation in tumour parenchyma under normal and inflamed conditions. This change 
is reversed with application of the TLR-7 agonist Imiquimod. Tumours treated with 
Imiquimod display increased E-Selectin, and subsequently CLA+ CD8+ T Cell infiltration, 
and reduced FOXP3+ T-Reg infiltration24,25. Interestingly, FOXP3+ T-Reg infiltration into 
tumour core appears higher in immunosuppressed solid organ transplant recipients and is 
associated with a worse prognosis – an effect not seen in other cancers18,19,24,26.  
 
Overactivity of immune cells has been linked to chronic inflammation and disease in non-
malignant conditions, and keratinocyte production of cytokines has been known to 
selectively recruit T cells to inflamed skin27. Cutaneous SCCs show a diverse population of 
T-Cells with low Ki-67, and varying CLA expression, suggesting migration from non-
cutaneous sources28. CLA+ T-Cells are present in high levels in the skin and act as 
memory cells to perpetuate immune reactions to stimuli, and have been implicated in the 
development and severity of psoriasis. 95% of the CLA+, CCR4+, CCR6 T-Cells show Th1 
polarization, and are present in a 7:1 ratio with Th2 cells24.  
 
	 18	
Peritumoral Inflammatory Infiltration 
The peritumoral inflammatory infiltrate demonstrates the microenvironmental changes that 
occur in response to chemokine expression without the impact of dysplastic and often 
hypoxic conditions more central to the tumour core. High Tumour Associated Macrophage 
(TAM) infiltration is correlated with increased TGF- β expression and Myeloid Derived 
Suppressor Cell (MDSC) presence29,30. These cells have been shown to prevent antigen 
specific T cell response and activation, particularly with regards to CD8+ T Cell function, 
and can furthermore regulate CCR5 dependent T-Reg infiltration via a CCL3/CCL4 
dependent pathway31–33. 
 
The presence of TAMs, MDSCs, and T-regs inhibit T cell anti-tumor activity,  are 
associated with worse prognosis, and can affect efficacy of chemotherapy and 
immunotherapy32,34,35. Interestingly however, Dendritic Cell presence is associated with 
improved prognosis. DCs attract CD8+ Cytotoxic T-lymphocytes (CTL), which attack 
tumour cells. Immature DCs are present in the tumour core, while mature DCs populate 
the peritumoral stroma, which may influence the capacity for CTL infiltration and effect36,37. 
 
The composition of immune cells in the tumour microenvironment differs between 
immunocompetent and immunosuppressed organ transplant recipients, and may impact 
on the differences in prognosis between these patient groups. The perineoplastic infiltrate 
is weighted towards Th2 dominance, inhibiting Th1 responses, which may result in 
peritumoral field change and permit higher recurrence rates, and more aggressive 
behavior. This is a consequence of reduced mRNA for Th1 and IL-17A, and contributes to 
a compromised local inflammatory response in the cSCC or Organ-Transplant Recipients 
(OTR)s38. Whilst fewer T-Regs generally correlates with improved prognosis, the use of 
the Calcineurin inhibitor Cyclosporine negatively impacts T-Cell generation39.  
 
In cSCC, TAM infiltration is increased via adhesion of monocytes to vascular endothelium, 
a process which is chemokine IL-8 dependent40,41.  Increased TAM infiltration is 
associated with worse prognosis in over 80% of clinical studies, and subsequently, so is 
increased IL-8 expression3.  
The presence of neutrophils in peritumoral/tumoral stroma is associated with tumour cell 
death and improved prognosis. CXC chemokines such as IL-8 stimulate neutrophil 
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chemotaxis and infiltration. TGF-β inhibits Tumour-Associated neutrophil (TAN) infiltration 
and is associated with a worse prognosis for the patient42–45. NK cells accumulate in tissue 
when stimulated by C-C chemokines such as Monocyte Chemoattractant Protein-1 (MCP-
1)46. Priming of NK cells by IL-18 likely induces them to increase expression of 
CCL2/CCL3, and attract DCs to the target area37. The presence of Tumour-Infiltrating 
Lymphocytes (TILs) constitutes improved prognosis for the many tumour types that display 
them47. They are attracted by expression of CCL2, CXCL16, CXCL9, CXCL10, and assist 
in inducing tumour regression via synergistic cytotoxic activity with CD4/CD8+ T cells37,48–
50. Interestingly, nitrosylation (and functional inactivation) of CCL2 is associated with 
defective infiltration of TILs and worsened prognosis, indicating an important role in this 
chemokine for tumour survival51. 
 
Failures of primary activation of immune cells by chemokines will lead to altered immune 
cell infiltration, and alteration of the host response to tumour cells. The degree of cytokine 
expression along the spectrum of keratinocytic neoplasia has not been well established. 
Theoretically there should be a reduction in successful cell signaling from early AK (known 
to have high rates of spontaneous apoptosis and gross tumour death) to the invasive SCC 
where tumour cells have seemingly unregulated cellular growth. 
 
The expression of chemokines in cSCC show increased proangiogenic and 
prolymphangiogenic factors, chemotactically attracting macrophages and circulating 
immune cells3. Ischaemia is a common feature in all invasive tumours that out-grow their 
blood supply, and thus require angiogenic stimulatory factors to maintain tumour growth. 
The expression of IL-8, Vascular Endothelial Growth-Factor (VEGF), Angiogenin, 
Fibroblastic Growth Factor (FGF) and Platelet Derived Growth Factor (PDGF) are 
inducible under hypoxic conditions. Anoxia induces transcriptional factor stability which in 
turn facilitates increased IL-8 expression1. Increased expression of these factors correlates 
with an increased microvessel density and subsequent improved blood supply to the 
tumour parenchyma55. The combination of an extrinsic pro-inflammatory microenvironment 
with intrinsically, genetically initiated pre-cancerous cells results in further alterations in 
gene expression, enhanced proliferation and resistance to apoptosis, and sustained 
angiogenesis of the tumour52. 
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On a molecular level, multiple pathways have linked chronic inflammation with malignant 
progression. Proteins can be activated by extracellular signaling, growth factors 
(Epidermal Growth Factor, EGFR) and cytokines (IL-6; IL-16; IL-22) to regulate gene 
expression and mediate survival, proliferation, invasion and angiogenesis of cancers as 
reviewed by Clark in 200824. Nuclear Factor of Activated T Cells (NFAT) acts to regulate 
inflammatory responses to stimuli via a wide range of pro-inflammatory cytokines, and has 
been experimentally induced by Ultraviolet-B (UV-B) wavelengths in HaCaT keratinocytes. 
The inhibition of this response results in reduced COX-2 protein induction and increased 
apoptosis in response to UV-B radiation53. Immune cell production of pro-inflammatory 
cytokines induce Signal Transducer and Activator of Transcription-3 (STAT3) and Nuclear 
Factor κβ (NF-κβ) – which have been shown to promote cell proliferation, inhibit apoptosis 
and contribute to cell survival in SCC cell lines54–56. The behavior of cytokines promoting 
tumour progression is further substantiated by enhanced tumour growth of IL-6 transfected 
human BCC, as well as malignant transformation associated with expression of G-CSF 
and GM-CSF in HaCaT keratinocytes57. Persistent autocrine and paracrine stimulation by 
CXC chemokines has previously been shown to promote pre-neoplastic progression to 
malignancy58. Receptor mediated tumour formation via chemokine expression has been 
associated with RAS mutations in response to pro-inflammatory cytokines IL-1; IL-6 and 
IL-11, and chemokine IL-859.  
 
The concept of intrinsic genetic damage being propagated by extrinsic stimulation has 
been exhibited in aggressive ovarian cancers, where rapid tumour growth results in 
hypoxic conditions. This induces genetic transcription of hypoxia-inducible factors (HIF) 
that further upregulates the transcription of angiogenesis promoting factors, such as the 
chemokine Interleukin-8 (IL-8)1.   
This propagation of tumour growth and survival through genetic manipulation by cancer 
cells has not been studied in cutaneous SCC and subsequently warrants further 
investigation. 
Cytokines and Chemokines 
 
Cytokine and chemokine function is fundamental to immune responses in the skin. 
Keratinocytes are the major source of cytokine production in the epidermis and coordinate 
cellular proliferation, ECM growth, communication, inflammatory infiltration and 
	 21	
angiogenesis. When released in excess, they can produce and propagate acute and 
chronic disease in a complex positive feedback loop54,60,61. Subsequently, dysplastic and 
hyperplastic growth results in an increased keratinocytic load, and an increase in potential 
cytokine production. 
 
 
 
Figure 3. The structure of CXC and CC Chemokines61. 
Chemotactic cytokines stimulate the above functions in immune cells, and attract their 
migration in a concentration gradient dependent manner62,63. Cytokines are induced by 
exposure to irritants, exhibiting an important role in epidermal and specifically keratinocytic 
response to noxious stimuli and disease of the skin64.  
Chemokine expression can be elevated in response to tumour burden as well as 
inflammatory cell migration and subsequent local production. Breast cancer displays 
elevated levels of TNF, which is majorly produced by macrophages. When chronically 
produced, this contributes to tissue remodelling and stromal development necessary for 
tumour progression. This local migration has been demonstrated to not only correlate with 
the extent of lymphocytic infiltration (CCL2/CXCL8), but also to localize regionally within 
the tumour itself (CCL3/4)54. High levels of neutrophil infiltrate correlate with the 
expression of IL-10; IL-17; TNF- α and, TNF- β and are detected in the precancerous 
microenvironment50,65–67.  
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Structural 
Subgroup 
Function Examples References 
C-X-C Important for neutrophil and/or T-
lymphocyte selective accumulation in 
inflamed skin, angiogenesis/angiostasis 
IL-8 
Gro-Alpha 
IP-10 
MIG 
CXCL5 
CXCL9 
CXCL10 
CXCL16 
Baggiolini et al., 199245 
Bornscheuer et al., 199668 
Waugh et al., 200844 
Tensen et al., 199969 
Park et al., 200270 
Zhao et al., 200262 
Lasagni et al., 200363 
C-C Attract monocytes, T cell subsets, 
eosinophils and basophils; 
proinflammatory 
MCP-1 
MIP-1a 
MIP-1b 
MARC (MCP-3) 
CCL20 
CCL21 
Carr et al., 199471 
Kim et al., 199550 
Menten et al., 200265 
Jing et al.,200366 
Maurer et al., 200467 
Kitahara et al., 201272 
Schlecker et al., 201273 
Chandrasekar et al., 201333 
Tsai et al., 201374 
Table 1. The C-C and C-X-C Chemokines 
 
Keratinocytic tumours are capable of producing large quantities of cytokines, both by virtue 
of keratinocytic load and dysplastic genetic changes altering protein expression. The SCC 
microenvironment suppresses myeloid DC function via increased IL-10 and TGF- β 
expression, as well as higher VEGF-A likely as a response to hypoxia, and attempt at 
neoangiogenesis21.  
 
 
The capacity of chemokines to influence the tumour immunophenotype relates to their 
stimulatory role for immune cell migration and extravasation. Their structure is significant 
for receptor functionality, and stimulation of particular cell subsets that exhibit these. The 
structural differences are based on the presence of terminal Cysteine-Cysteine residues, 
and the substitution of a variable amino acid motif in the C-X-C subgroup (Figure 3), and 
have functional manifestations described in Table 1. Further specific structural differences 
appear to have impacts beyond chemotaxis, extending to trigger protein transcription and 
cellular behavioural shifts. The presence of a Glutamine-Leucine-Arginine (ELR+ motif) 
stimulates angiogenesis, and even its relative absence through overexpression of 
CXL9/CXCL10 (both ELR-) has been noted to suppress this behavior in a murine Burkitt’s 
lymphoma model75,76. The significance of angiogenesis to tumour survival and progression 
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is highlighted by the increase in microvessel density, neovascularization of peritumoral 
stroma, and worsened prognosis in Melanoma and Pancreatic Cancers associated with 
increased CXCL1/CXCL8 expression77,78. 
 
Non-Chemotactic functions of Chemokines 
Beyond stimulating cellular extravasation and proliferation, Chemokines can influence the 
behaviour of endothelial and stromal tissues, and this effect is well demonstrated by 
VEGF, which acts to increase angiogenesis and vascular permeability. Expression is 
markedly increased in SCC compared to KA and BCC, and significantly correlated with 
degree of tumour differentiation79,80. It likely enhances tumour angiogenesis by increasing 
microvessel density, which is associated with increased expression of Vascular 
Endothelial Growth Factor (VEGF) mRNA, and is higher in SCC than BCC81. 
Prognostically, higher levels of VEGF and Microvessel Density (MVD) are associated with 
worse overall mortality in HNSCC, but interestingly not with risk of metastasis82.  
 
The level of IL-8 expression has been shown to impact growth potential of tumours. 
Human Ovarian Cancer cell lines constitutively producing IL-8 have a higher proliferative 
rate than those with lower levels1. This production is increased by the hypoxic conditions 
created by high turnover tumours that proliferate faster than their blood supply can 
support. Ovarian cancer cells display IL-8 mRNA and protein expression highest in areas 
adjacent to necrotic and hypoxic zones1.  
 
This stimulation of angiogenesis appears fundamental to tumour progression to invasive 
disease. In advanced disease, peripheral tumour cells divide and proliferate in concert with 
neoangiogenesis and the proliferation of new endothelial cells. Whilst the capacity of the 
tumour to induce angiogenesis has not previously correlated with malignant staging, its 
absence precludes the expansion of the tumour mass, regardless of the proliferative 
capacity of cells. This dependence on enhanced blood supply through increased MVD has 
been shown with VEGF, and appears particularly important for the progression of 
premalignant conditions to invasive disease14. Furthermore, the blockade of NF-κβ 
signaling suppresses IL-8 and VEGF expression and reduces ovarian cancer 
tumorigenicity, highlighting their implication in disease progression2. 
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Interleukin-8 
Interleukin-8 is a ELR+ C-X-C chemokine produced primarily by macrophage and 
mesenchymal cells in response to a range of factors: macrophage-cancer cell interaction; 
infection; inflammation; ischaemia; and, trauma83. 
It can also be produced by keratinocytes in response to the above, but also to UV light 
(280-320nm), explaining its presence in sunlight induced cancers84,85. 
Otherwise known as Neutrophil-Activating Peptide-1, the ELR+ CXCL8 (IL-8) is primarily 
produced by macrophage and mesenchymal cells in response to inflammatory stimuli44,75. 
This has been shown to stimulate haptotactic transendothelial migration via a 
CXCL1/CXCL2 dependent mechanism, both ex-vivo and in melanoma and prostate 
cancers86–88. This mechanism has been experimentally blocked via administration of anti-
IL-8 antibodies with good effect ex-vivo, however more recent studies using anti-CXCL-1/-
2 to reduce neutrophil migration in respiratory disease has also been promising89. 
 
Whilst well known to have significance in the activation of neutrophils, lymphocytes and 
macrophages, it has a significant role in cancer progression, angiogenesis and 
metastasis90. Studies of Non-Small Cell Lung Cancer demonstrate a dose dependent 
response to IL-8 via infiltrating TAM density and MVD, which correlated negatively with 
patient survival91.  
IL-8 expression is enhanced in response to ischaemia stimulated Hypoxia-Inducible Factor 
1a gene transcription, commonly occurring in the peripheral margins of tumours 
outgrowing their blood supply due to rapid proliferation1,92–95. Anoxia induces an enhanced 
binding activity of transcriptional factors AP-1 and NF-Kκβ in aggressive melanoma cells 
lines, which in turn induces IL-8 expression94,95. This effect has been observed in rapidly 
growing ovarian cancer cells in response to hypoxia, and subsequent experimental 
blockade of IL-8 reduced tumorigenicity1,2.  
Macrophage Inflammatory Proteins-1α and -1β 
 
The Macrophage Inflammatory Proteins-1α and -1β are related members of the C-C 
chemokine subfamily, and besides keratinocytes, in the skin are produced largely by 
Antigen Presenting Cells (APCs)67. They show differential signaling at CC-Receptors 
CCR1, CCR2, CCR3, and CCR5, based on their terminal NH(2) residues66.  
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These proteins have Chemotactic/ Proinflammatory effects, roles in resistance to bacterial 
infections. They are up-regulated by IL-1ß, TNF-a, and down regulated by Tacrolimus, and 
PGE272,66,33. Inhibition of expression by PGE2 (anti-inflammatory), suggests an 
inflammatory action further supported by in-vivo studies of dendritic cells stimulated with 
LPS and Peptidoglycan66.   
Studies of lymphoma models show high levels of CCL3/CCL4 expression by large 
populations of MDSCs accumulating in organs during tumour progression. Increased 
levels of Monocyte-MDSCs expressing CCL3/4 correlate with increased tumour-infiltrating 
T-reg presence. A deficiency in CCR5 (CCL3/CCL4 receptor) reduces T-reg infiltration and 
tumour growth73. A reduction in CCR5 ligands (CCL3/4) would predict a reduction in T-reg 
presence in peritumoral inflammatory infiltrate40,73,38. T-reg presence has been correlated 
with worse prognosis in cSCC, Therefore, on examination of the chemokine profile of 
advanced SCCs, one would expect to find increased CCL3/CCL4 levels, with increased T-
reg presence, and a worse prognosis in these tumours.  
 
Methods 
 
Literature Review – a broad review of the literature was performed via Medline; 
bibliographic databases; academic abstracts; and, use of the University Library. Key 
search terms are listed in pre-text. Given the broad scope of the topic and minimal existing 
literature, no publication date limitations were put on the papers cited.   
 
Population 
Patients were recruited from the private practice of a single Plastic and Reconstructive 
Surgeon. Patients were included if they had skin lesions suspicious for keratinocytic 
malignancy of squamous differentiation. Patients were excluded if they displayed lesions 
that were either biopsy proven or clinically distinct Basal Cell Carcinoma or Melanoma.  
Initial conceptual plans to analyze the four major histopathological groups shown below 
led to a plan for 25 of each lesion subtype to be collected. After significant numbers of 
lesions being histopathologically different to preoperative clinical assessment – this 
number was not pursued, in an attempt to facilitate completion of the project.  
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Figure 4. Peritumoral punch biopsy sampling technique. 
 
Sampling/Sampling Procedures 
After discussion between the Surgeon and involved Pathologist, lesions were sampled 
with a 4mm punch biopsy from either the 12 o’clock or 6 o’clock margin of the tumour 
(Figure 4). This was in an effort to preserve sound oncologic practice and not impact 
histopathological diagnosis or patient care. All pathology bloc specimens were then kept 
for a minimum of 5 years per Pathology Company policy. 
 
Recruitment, Partcipation Data Collection 
Patients were consulted on the day of their surgery preoperatively, and informed regarding 
the aims of the study, the techniques involved, and potential impact on pathological 
diagnosis.  
 
!
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Data Storage 
De-identified data including patient information, consent forms, and specimens were kept 
on laboratory campus in labeled storage, and hard-drive format. This information will be 
stored for a minimum of 5 years per organizational policy.  
 
Ethical Consent Process 
Ethical applications were approved by the University of Queensland, and Greenslopes 
Hospital Ethics Committees, and were updated every 12 months in compliance with Codes 
of Conduct.  The copies of patient consent and data forms are available in the appendix.  
 
 
 
 
 
 
 
Lesion Assessment 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Histopathological grading and thickness of lesions. 
 
	 28	
Lesion H&E histopathology slides scanned at 20X magnification using the Olympus VS120 
slide scanner, and analyzed using Aperio image software. Thickness was measured from 
the granular layer to the deepest part of tumour. Histopathology reports were gathered 
from private pathology laboratories, and were confirmed by re-analysis by a Consultant 
Dermato-pathologist (HS). 
 
Immune Cell Grading  
Immune cell infiltration was measured visually by duplicate histological assessment of 
H&E paraffin mounted slides of specimens (HS & MY), and scored from 0 to 3 for 
presence and density of immune cell infiltrate, utilizing a modified immunoscore for skin 
cancer96,97. 
 
Specimen Collection / Processing 
Consented patients underwent surgery per normal oncologic practice. Excised specimens 
were biopsied using a 4mm punch biopsy (Figure 5). These specimens were transferred to 
500µl cold PBS (< 4 degrees celsius) containing a broad-spectrum non-toxic protease 
inhibitor cocktail (EDTA-free “Mini-complete protease inhibitor cocktail” from Roche). 
Samples were kept fresh and cold during transit. Within 2 hours of receipt, these samples 
were dry-weighed, homogenized into solution (Figure 6) and deep frozen (-80 degrees 
Celsius).  
 
Figure 6. samples were homogenized into solution within their 500µl aliquots. 
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To standardize samples, lesions were weighed, and the concentration of chemokine in 
pg/ml via flow cytometry was analyzed. Each specimen was dry-weighed before 
homogenization into solution, and precipitates were tagged with the Multiplex chemokine 
assay (LEGENDplexTM (Fig 7)) for the 13 chemokines listed in Appendix 1.  Results from 
FACS were standardized based on weight into pg/g of tissue for comparison.  
 
Initial pilot study utilized a multiplex immunoassay with antibodies to IL-8; CCL3; CCL4; G-
CSG; MIG; MCP-1 from eBioscience (Affymetrix, San Diego, USA). After production of 
this kit was ceased, the second and third validation studies used a dual bead multiplex 
immunoassay against human chemokines IL-8; IP-10; CCL3; CCL4; CCL11; TARC; MCP-
1; RANTES; MIG; ENA-78; GROα; I-TAC from BioLegend, San Diego, USA (Figure 7.). 
Homogenized cells in the PBS-protease inhibitor solution were tagged with biotinylated 
detection antibodies. These were then sandwiched with capture-bead Streptavidin-
phycoerythrin antibodies (SA-PE) to bind the biotinylated antibodies to enhance the 
fluorescence signal, and then analyzed using a Flow Cytometer (FACSAria III Beckton 
Dickinson, NJ, USA). All specimens were tested in duplicate. The concentration of each 
chemokine was then determined using a known standard curve from the LEGENDplex™ 
data analysis software. 
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Figure 7. FACS Standard Curves – BioLegend LEGENDPlex Chemokine Assay 
 
 
 
Statistical Analysis  
Data obtained from flow cytometric analysis are expressed as mean ± standard deviation 
in pg/ml. This was converted by specimen weight to a pg/g value for relative comparison. 
Due to significant skewing of data, these values were logarithmically transformed.  
Lesion thickness was expressed continuously in millimetres, and subsequently a Pearson 
correlation test was used to interpret relationship between these two factors. Given the 
difficulty in diagrammatic representation of this data, a line of best fit was chosen via linear 
regression.  
Differences in expression between the histopathological subgroups, infiltration scores and 
body regions were determined by one-way ANOVA and Holm-Sidak multiple comparison 
test. A value of p < 0.05 was deemed significant. Multivariate analysis was performed 
using Linear Regression using Prism software (La Jolla, CA, USA).  
All statistical methods were validated by an independent biostatistician (QFAB, A Bernard).  
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RESULTS 
 
Patient demographics 
 
Histopathology Non-dysplastic  14 
AK 11 
IEC/ SCC in situ 18 
SCC 25 
 
Total 
 
67 
Age range 
(mean) 
45-96 (78.45) 
 Gender 51M : 16F 
Table 2. Patient demographics + Histopathology 
 
A total of 33 patients ranging in age from 45-96 years old (mean 78 years old) provided 67 
specimens for analysis.  Non-dysplastic samples were comprised of 3 non-sun-exposed 
skin from a single patient; 5 samples of sun-exposed non-dysplastic tissue from a single 
patient who was SCC free; and 6 samples of non-dysplastic scar from re-excised tissue – 
at sites of previous SCC excision. 16 patients had multiple lesions (>2), and of these, 5 
patients had >5 lesions sampled. There was a significant gender disparity – most probably 
due to the 51 specimens coming from 24 men. 11 of these men had >2 lesions, averaging 
3.45 lesions per patient (total of 38 from 11 men). Of the women, 8/16 specimens were 
from 2 patients with normal skin specimens. The other 8/16 lesions came from 7 women 
and subsequently displayed a lower tendency to have more lesions. There was a 
disparate number of more invasive SCC lesions of the samples taken, which represents a 
sampling bias, resulting from patients referred for a higher level care from a specialist 
surgeon for more aggressive tumours, and not for less invasive AK/IEC/SCC in situ 
lesions.  
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Chemokine expression increases with increasing lesion thickness 
Samples ranged in thickness from 0.1mm to 7.5mm (mean 1.175mm +/- 1.597). This was 
inclusive of dysplastic and normal skin. The expression of IL-8 and MIP-1α correlated 
significantly with increasing thickness (Pearson coefficient r = >0.4, p = 0.0003***), whilst 
MIP-1β did not. Thicker lesions contain higher numbers of keratinocytes and subsequently 
possess more potential for increased chemokine expression. This difference in correlation 
is potentially due to the pro-inflammatory impact of IL-8 and MIP-1α, also correlating 
strongly with an increase in inflammatory infiltration (Fig 8).  
 
Despite significant individual correlation tests, Multiple linear regression modelling showed 
a significant correlation of chemokine expression with lesion thickness (p = 0.017) but not 
infiltration scoring (p = 0.147).  
 
Figure 8. Correlation plots of log Chemokine expression vs lesion thickness. Pearson coefficient r on figure. Dots 
represent individual specimens with no differentiation between histopathological groups. (n = 67) 
 
Histopathological severity impacts chemokine expression 
Worsening histopathology was significantly associated with increasing chemokine 
expression in IL-8 and MIP-1α, but not MIP-1β (Fig 9). This was again likely a result of the 
increased presence of tumour-progressive cell types, secreting factors such as IL-8 that 
promote angiogenesis and assist in evading apoptosis. This increase with worsening 
histopathological grading supports the model of keratinocyte:cancer cell interactions 
increasing chemokine expression – more dysplastic cells potentiate the release of proteins 
for various roles54,60,98. 
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Figure 9. Chemokine expression vs Histopathological stages (Mean value (straight line) + Kruskal-Wallis One-Way 
ANOVA p values on figure). Dots in each column represent samples from each histopathological group on X axis. (n = 
normal skin (14); AK (11); IEC/SCCis (18); SCC (25)). 
 
SCC is thicker and more infiltrated by Immune cells  
Immune cell infiltration was graded on a scale from 0-3 (mean of 1.7716).  
Lesions were significantly thicker the more dysplastic they were, most significantly seen in 
the invasive SCC group (Fig 10).   
 
 
 
 
 
 
 
 
 
Figure 10. Histopathology Group vs Lesion Thickness. Box & whiskers plot graphically represented, with Kruskal-Wallis 
One-Way ANOVA p values on figure. (n = normal skin (14); AK (11); IEC/SCCis (18); SCC (25). 
Thicker lesions were however not more infiltrated – this effect was maximal with lesions 
graded 1-2 (p = 0.0134*). This likely reflects the more infiltrated AK/IEC/SCC in situ 
lesions displaying immune cell attempts at clearance of the disease (Fig 11). Multiple 
linear regression modeling failed to establish a significant relationship between infiltration 
(p = 0.15) and histopathology (p = 0.4) with increasing lesion thickness. By failing to link 
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the two, the univariate anaylsis of histopathology and increasing lesion thickness supports 
histopathological grading and prognostic scores for cSCC.  
 
 
From a prognostic standpoint, increasing thickness and worsening histopathology is 
correlated to increased risk of distant metastasis and a reduced overall survival99.  
Identifying the significance of chemokine expression in relation to prognostic outcome 
would provide a significant basis for further investigation into potential therapeutic targets 
for these patients.  
Figure 11. Thickness of lesions according to infiltration scoring. Box & whiskers plot graphically represented, with 
Kruskal-Wallis One-Way ANOVA p value on figure. Infiltration score (n  = 0 (7), 1 (21), 2 (19), 3 (20) 
 
Infiltration score correlates strongly with chemokine expression 
 
Figure 12. Chemokine expression by infiltration scoring. Mean value + SEM superimposed on values with Kruskal-Wallis 
One-Way ANOVA p value on figure. P value (* = <0.01; ** = <0.001, *** = <0.0001). Infiltration score (n  = 0 (7), 1 (21), 2 
(19), 3 (20) 
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One-Way ANOVA of increasing infiltration scoring correlated with the expression of IL-8 
and MIP-1α, but not MIP-1β (Fig 12). More inflamed lesions produced higher amounts of 
the two more pro-inflammatory chemokines. These severely inflamed lesions did not 
necessarily make up the highest histopathological grading, the highest mean infiltration 
score was recorded in IEC/SCC in situ lesions (p= <0.0001***) (Fig 13).  
  
 
  
 
 
 
 
 
 
Figure 13. Infiltration scoring of histopathological groups. Box & whiskers plot of range & mean with Kruskal-Wallis One-
Way ANOVA p values superimposed on figure. (n = normal skin (14); AK (11); IEC/SCCis (18); SCC (25)). 
 
 
Tumour location does not impact lesion thickness or infiltration score 
 
Specific tumour location was sub-group analyzed by physical region. No significant 
differences in chemokine expression, tumour thickness, or immune infiltration existed 
between regions. There was no difference in the expression in sun damaged vs non-sun 
damaged skin samples, likely due to a low sample size. Despite an anatomical difference 
in the thickness of the dermis and structural skin unit across these regional locations, no 
significant difference in chemokine expression was evident across the three groups in 
One-Way ANOVA (p values [ IL-8 = 0.1627; MIP-1 α = 0.6437; MIP-1 β = 0.6997] ).  
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Figure 14. Chemokine expression of lesions from different tumour locations. Mean graphically displayed on figure. (N = 
scalp (22), Face (26), Rest of Body (18)). 
 
 
Tumour location did not significantly correlate with infiltration score (Pearson r = 0.04696) 
(Fig 15b). Theoretically a reduction in the capacity of poorly vascularized tissue in the feet 
and legs of patients with peripheral vascular disease may impact on relative immune 
response, no difference was seen in the specimens. This was a sample bias, due to the 
majority of significant lesions referred to private Plastic Surgeons being on the Head/Neck 
and cosmetically sensitive areas. More variation in response, particularly on the lower 
limbs in an older cohort of patients would be expected.  
 
 
Figure 15. a) Lesion thickness relative to regional location. B) Lesion infiltration score relative to body location. Pearson 
Correlation r value superimposed on figure. (N = scalp (22), Face (26), Rest of Body (18)). 
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Intrapatient	Variability	of	Chemokine	Expression		
While lesion thickness, immune infiltration and dysplastic change have attempted to 
analyze the impact of these factors; they have been approached as if each lesion was 
from a discrete patient. Table 2 describes the patient cohort, and the large number of 
patients with more than 2 lesions sampled at a time. As a significant number of patients 
had multiple lesions, and the majority of those were males, there exists a high risk of 
sample bias. To remove the possibility that 1 patient may have consistently high levels of a 
chemokine or chemokines and skew the results, an analysis of intrapatient variability was 
undertaken.  
 
5 separate patients had over 5 lesions each excised, the results of which are listed in 
Appendix 2.  As these patients did not have individual controls, and had a variety of 
numbers of each type of lesion, no statistical tests were uniformly available to compare 
each group. Consideration was made towards converting data to Z scores in order to 
compare the mean data – however sample size remained to small and inconsistent for 
comparison. What can be established from the visual representation of the results is the 
high degree of variability between different specimens in the same patient. Figure 17 
displays the high variation between lesion thickness and chemokine expression in all three 
groups in a single patient. These 5 specimens represented 3 of the histopathological 
groups as shown in the legend. Tissue histopathologically described as normal had similar 
output to that of AK/IEC/SCC in situ lesions. This may reflect sampling bias, as no normal 
tissue was intentionally excised from this patient, and may have clinically represented a re-
excision site of a previously biopsied specimen that, whilst having no malignancy, 
represented an area of post-operative inflammation. The comparison between 
histopathological groups is displayed in Appendix 2. There was no significant difference in 
the chemokine expression of lesions in each patient, suggesting this may have more to do 
with individual patient reaction to inflammatory or cancer stimuli, however without truly 
representative control samples of non-damaged tissue from each patient this cannot be 
formally commented on. 
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Figure 16. Intrapatient variation of chemokine expression in lesions of varying thickness. 
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Discussion 
 
Tumour thickness was significantly correlated with increasing chemokine expression 
amongst all three groups (Fig 8).  This is likely a demonstration of increased keratinocytic 
translation of chemotactic proteins in response to an increased local tumour burden in 
these lesions, and mimics the theory of increasing chemokine expression by keratinocytes 
due to hyperkeratosis often seen in keratinocytic dysplasia, and also due to keratinocyte: 
Cell interaction causing positive feedback and increased expression54,60,98. Peripheral 
ischaemia and resulting hypoxia resulting from rapidly proliferating tumours have been 
shown to reactively express pro-angiogenic chemokines and growth factors1,78,95. As IL-8 
has been previously shown to increase in hypoxic tissue in response to an increase in 
HIF-1α expression, the increase demonstrated by the thicker lesions in this study support 
this model, despite significant variation in expression with progression1,93,100.  
 
Theoretically a thicker lesion, with increased dysplastic change, would have a higher 
element of tumour burden and immunogenic stimulus to support thicker inflammatory 
infiltrate. Whilst lesions with an infiltration score of 2 were significantly thicker than those 
scoring 0 (Fig 11, p = 0.0134). This relationship did not correlate in higher infiltration 
scores of 3. Inflammation is a feature common to advanced tumours – a chronic 
inflammatory cell infiltrate has been described both in peripheral stromal tissue and within 
the body of the lesion in a variety of cancers101. There is a significant inflammatory 
response evident in progressive stages of AK/IEC/SCC in situ. Inflammation is associated 
with the progression of AK to invasive SCC102,103. This inflammation is more than likely a 
pre-requisite rather than a result of cancer, and can be associated with cellular attraction 
and growth factors necessary for chemotaxis, activation and proliferation of immune 
cells15,54,104. 
 
Increasing dysplastic change across the groups was shown to significantly (p = <0.0001) 
correlate with both increasing inflammatory infiltrate and lesion thickness (Fig 10,13), 
which mimics previous reports in the literature in both OTR and immunocompetent 
populations57. The loss of a homeostatic chemokine expression has previously been 
shown to result in unregulated immune cell infiltration and failure of organization105. 
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It is likely that increased expression of IL-8 in cSCC may result in increased infiltration of 
leukocytes that potentially will produce their own growth factors and chemokines, creating 
a positive feedback cycle, which results in angiogenesis, cell proliferation, and expansion 
of the tumour mass.  
 
The inflammatory infiltrate increase does not initially support the idea of increased 
inflammation rejecting the growth of AK. This effect can be induced by topical therapies 
such as Diclofenac and Imiquimod. Both AK and SCC commonly display an interface 
dermatitis characterized by CTL infiltration106. This inflammatory stimulus in AK has been 
shown to precede malignant transformation to SCC and represents an attempt at immune 
rejection of these lesions. 50% of inflamed, clinically diagnosed but tender and 
erythematous AK are actually histologically SCC. Attempts to induce cytotoxic rejection 
fail, and these lesions display significant inflammation displayed by higher levels of CD3+; 
CD4+; CD8+ lymphocytes when compared with asymptomatic AK103.  
 
Capacity to mount a significant immune response in the case of immunosuppressed 
patients factors heavily in both the clinical and pathological patterns of disease seen in this 
cohort. Post solid-organ transplantation, risk of cSCC increases by 65-100 fold, and the 
ratio of BCC:SCC reverses from 3:1.7 to 1:29. Increased ratios of T-Reg:CD8+ has been 
shown to contribute to more aggressive cSCC growth in OTRs107,108. High proportions of 
FOXP3+ T-Regs (>50% of T cells) are present in SCC – and much more than is seen in 
AK lesions109.  
 
Fundamentally, Clark et al demonstrated 50% of T-Cell infiltrate in untreated SCCs were 
FOXP3+ T-Regs, that displayed minimal Ki-67 staining, and suggests these cells are 
recruited, and not produced locally. Tumours pre-operatively treated with the immune-
modulator Imiquimod showed reduced FOXP3+, CD39, CD73, IL-10 and TGF- β levels – 
down staging their inflammatory profile28.  
 
Prognostically, the literature provides varied outcomes with regards to immune infiltrate 
phenotype. Gonzalez-Garcia et al demonstrated that increased density of inflammatory 
infiltrates is correlated with protection from development of local recurrences and improved 
survival in HNSCC, and this was mimicked by Tosolini in regards to these cell populations 
in Colorectal Cancer18,110. This contrasts from data by Kosmidis et al, who found reduced 
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FOXP3, TGF-B, and CD4 mRNA in OTR SCCs, and increased local recurrence in 
aggressive tumours39.  Studies of colorectal cancer have shown survival benefits with 
increased FOXP3+ T-Reg infiltration17, and more relevantly – reduced infiltration of 
FOXP3+ in cutaneous SCC correlates with worse prognosis57. Conversely – Gerber et al 
demonstrated a negative prognostic value of FOXP3 expression in melanoma, 
independent of other significant factors111. 
 
Immune cell migration in response to chemokine expression has been both demonstrated 
and rejected experimentally and clinically in other tumours40,46,98. Despite our data 
supporting an increase in inflammation with increased dysplasia (Fig 13) we have not 
examined for cellular composition beyond histological examination. Figure 12 
demonstrates significant correlation between inflammation and chemokine production of 
MIP-1α and IL-8, and a lack of the same in MIP-1β. However we are unable to infer where 
the chemokine production is coming from, inflammatory cells or tumour burden. The 
increase in chemokine production without relative increase in immune infiltration may 
relate to recently described atypical chemokine receptor function at sub-receptor CCR-D6, 
which suppresses inflammatory response. This was not examined for in this study, 
however may represent a target for future research51,112 
 
Increasing thickness correlated significantly (p <0.05) with IL-8 expression when analysing 
immune infiltration scores separately across the groups (Fig 8, Fig 12).  While variance 
was significant across all groups, multiple comparison tests failed to demonstrate 
significant differences in MIP-1β between infiltration scores. IL-8 and MIP-1α support a 
worsening pathological diagnosis being correlated with a higher immune infiltration and, 
separately, a thicker lesion correlating with a denser infiltration and higher chemokine 
expression. Mühleisen et al showed an increase in the thickness of inflammatory infiltrates 
with progression from IEC to invasive SCC57. 
 
One potential cause for a lack of significant correlation between increased MIP-1β and 
effective immune infiltration is the effect of protein aggregation observed in MIP-1α. At a 
concentration of 100ug/ml, MIP-1α exists as a dodecamer in physiological buffers. 
Sequential dilution progressively breaks up the aggregate via tetramers and dimers to the 
monomeric form. Aggregation of MIP-1a is a dynamic and reversible process and it 
appears that the chemokine is exclusively in the monomeric form at physiologically 
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relevant concentrations (less than 100ng/ml). While a plateau or decrease in expression 
was not observed in MIP-1α, the two proteins contain 58% identical amino acids, and 
theoretically may be at risk of the same phenomenon113.  This effect has not been 
described in IL-8 before.  
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Conclusions 
The expression of the chemokines IL-8 and MIP-1α correlates with increasing thickness, 
infiltration and histopathological severity in cSCC. These effects were not demonstrated 
with MIP-1β.  
 
Invasive cSCC lesions were thicker and more infiltrated by immune cells than their 
precursor lesions (p = 0.005***). IEC/SCC in situ lesions were the most highly infiltrated, 
which likely represents an attempt by the immune system to reject these malignant cells, 
and which process has failed in the more invasive cSCC lesions. The continuing increase 
in IL-8 and MIP-1α seen with increasing histopathological severity may be a consequence 
of keratinocyte: cancer cell interactions stimulating increased expression. However, the 
increase in size of more advanced lesions causes greater areas of ischaemia and induces 
the transcription of HIF-1α, which in turn stimulates IL-8 expression in an attempt to 
increase neoangiogenesis and improve blood supply.  
 
Whilst tumour location did not significantly impact chemokine expression, this may 
represent a sampling bias, as patients referred for Plastic Surgery to remove these 
cancers are more likely to have lesions in cosmetically sensitive areas such as the 
Head/Neck and Face removed, and this was reflected in the regional breakdown. The lack 
of lower limb lesions in an elderly age group represents a further sampling bias. The 
prevalence of peripheral vascular disease and poor blood supply to limbs has an unknown 
impact on the capacity of immune cells to mount a response to cancer cells by chemokine 
expression. Despite patients being screened for significant medical comorbidities, studies 
of chemokine expression in cutaneous atopic and inflammatory conditions requires further 
comparison between the levels expressed between these and malignant diseases.  
 
This study is generalizable for future studies to draw conclusions from – the high ratio of 
males: females is representative of the epidemiology of disease in the population, and the 
multiplicity of lesions on males is unfortunately endemic of this gender. The lack of control 
samples, and immunosuppressed patients represents a limitation which should be 
factored in to future research on this topic. 
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This study has effectively answered the question of whether or not chemokine expression 
in cutaneous SCC is affected by tumour thickness in a quantitative manner. However, 
qualitatively, the functional impact on tumour immune phenotype relative to the attracting 
chemokines is yet to be established. Given the known prognostic implications of 
chemokine expression and tumour cellular composition in other cancers, future studies 
should aim to identify the cell types present in response to chemokine expression.  
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Appendix 1 
 
 
 
Appendix 1. Chemokine analysis (pg/ml) for samples studied. Corresponding lesion 
Thickness and Infiltration scores in table. De-identified source data stored on private 
locked server 
Prof	Soyer	Path Thickness	(mm) Infiltration Body	Region IL-8	pg/gram MIP-1a/gram MIP-1b/gram IP-10/gram Eotaxin/gram TARC/gram MCP-1/gram RANTES/gram MIG/gram ENA-78/gram MIP-3a/gram GROa/gram I-TAC/gram
AK 0.1 1 face 181.41 211.88 167.2086257 24601.23 542.87 1152.32 1557.93 4489.30 1207.94 72.22317303 784.19 700.4963204 1072.565463
AK 0.1 1 scalp 1317.88 329.26 202.1937086 31012.83 1355.75 6581.13 4389.90 6169.29 4375.41 87.33443709 2581.54 1800.910596 2586.92053
AK 0.1 1 scalp 4545.27 258.93 179.7938903 50187.15 1143.72 5596.43 4814.50 5342.47 14965.59 77.65918292 5201.88 2918.476261 2857.747516
AK 0.2 1 scalp 304.26 499.16 235.3649723 52302.58 1265.48 2144.54 2436.28 5435.56 10001.20 101.6622501 1848.47 2519.633823 1309.56396
AK 0.2 2 scalp 381065.05 3405.31 554.6574288 59297.15 6243.65 8681.68 9303.31 9989.99 13068.90 73392.22479 8013.47 16084.68052 3389.915319
AK 0.1 1 scalp 28029.29 1319.91 188.2829061 78062.63 1750.24 2214.88 12817.31 5694.16 18791.10 568.5103103 5548.47 2812.29524 1751.011756
AK 0.1 1 scalp 13255.50 402.48 208.7160863 113380.26 963.90 1302.29 8268.32 7795.56 28680.62 404.8280282 8358.26 2117.282632 2278.359325
AK 0.2 1 scalp 25942.79 407.41 323.0820106 216839.29 786.71 2168.65 5765.21 316.14 42765.87 139.5502646 6807.54 2460.978836 2747.354497
AK 0.2 3 face 3382.91 1357.29 548.241206 502924.62 6816.58 16264.32 16301.51 19800.00 130622.61 282.9145729 8669.85 7089.949749 24192.46231
AK	(could	be	re-excision) 0.1 2 leg 856.95 570.18 328.0725319 26505.71 1508.39 524.85 3372.73 9309.27 3041.97 141.7058428 4282.74 1374.412357 2900.268637
Hyperplastic	AK 0.1 3 face 107082.74 1528.44 661.926309 65207.50 5017.13 5368.13 16008.08 38434.07 21288.95 1021.008403 25123.46 10355.52683 6796.703297
IEC 0.4 3 face 21237.93 1086.79 413.6325148 119894.58 5316.26 4488.57 37926.33 19844.62 45267.57 1277.730737 12433.95 4417.442845 6923.793395
IEC 0.5 3 scalp 482694.78 5029.25 3838.127743 105783.03 8049.24 4215.02 12579.23 14625.06 62919.06 5988.785958 6810.82 60480.7411 7589.468552
IEC 1.2 3 scalp 38028.06 1778.70 3099.489796 638278.06 4943.24 4039.54 28493.62 55460.46 750734.69 277.4234694 10998.09 20343.75 60670.91837
IEC 2 3 scalp 20652.28 1623.10 900.6079027 274127.66 26154.10 2896.96 123227.05 39482.07 118072.04 5564.133739 1706.08 13314.28571 10231.61094
IEC 1.2 2 face 28353.35 720.64 324.1539482 332057.07 969.14 2092.24 4403.12 2739.55 26455.54 140.0132714 2532.18 9353.019244 1919.708029
IEC 0.5 3 scalp 14603.26 517.56 408.4448161 287981.61 1852.42 719.06 5573.16 10987.88 66541.81 338.6287625 1142.98 1711.120401 2078.595318
IEC 0.8 3 face 36676.06 2477.99 262.2114868 146126.41 3316.69 15408.21 16867.15 5473.43 35498.12 794.1492217 7450.89 6097.42351 8263.01664
IEC 0.8 3 face 116229.21 1269.54 271.7663421 234252.57 2494.85 5465.92 15180.53 6349.65 31150.49 526.286509 8726.56 7876.216968 5270.375522
IEC 0.2 3 scalp 141121.66 710.88 233.0629771 15610.21 2372.14 1009.30 10697.28 9436.31 6397.19 1104.007634 4333.02 10702.52863 1475.429389
IEC 0.5 1 face 19296.95 827.48 372.9007634 37992.75 2850.38 3727.48 4850.38 19358.40 10212.21 365.2671756 13945.04 6514.885496 3816.030534
IEC	(Bowen's	Disease) 0.8 3 arm 16232.26 790.66 366.2955687 130077.28 3001.09 3630.87 10288.15 18888.02 46096.05 408.6444008 17679.33 4380.048024 11263.91618
massive	cluster 6 1 leg 141409.21 1205.93 517.2048703 85316.57 4944.42 1832.19 12235.57 16716.78 8615.14 1049.232398 5408.68 12552.67337 3824.775013
Norma	(AK)	at	edge 0.1 1 face 6181.26 287.95 287.9457707 221542.59 1005.60 1751.25 3963.45 4541.70 15991.45 791.0403772 1529.91 1206.307103 1577.365164
normal 0.1 1 scalp 25064.17 304.15 480.0946548 44422.33 988.59 3771.99 9928.45 15582.13 21468.96 269.0701559 6000.84 3450.02784 2934.716036
Normal	(inflamed	excision) 0.5 2 face 196990.82 8904.94 1432.470588 83344.47 7170.59 23676.47 53247.06 48068.47 38987.29 43360.47059 6778.59 27319.76471 4056.941176
normal	(severe	elastosis,	AK	at	the	edge)	0.1 1 scalp 34155.61 657.73 319.3854201 101898.99 1729.00 5298.79 12294.21 29801.24 69127.82 1160.183066 12050.67 1338.01896 8905.524681
normal	skin 0.1 0 thorax 385.85 511.07 284.5078626 11696.85 1668.61 4195.40 3596.10 16075.71 752.77 122.8887595 1193.65 1685.497962 962.7256843
normal	skin 0.1 0 thorax 207.91 362.82 208.7606838 7180.77 1145.51 801.92 1352.14 1981.41 585.68 90.17094017 808.55 1788.675214 542.0940171
normal	skin 0.1 0 thorax 264.98 545.48 266.0675381 4268.52 314.00 675.93 784.04 1342.32 698.26 114.9237473 618.19 1114.651416 448.8017429
normal	skin 0.1 0 face 449.94 422.72 286.0070258 8060.01 1206.67 626.76 2689.70 3478.92 393.74 123.5362998 596.02 1198.185012 469.8477752
normal	skin 0.1 0 face 506.32 301.08 301.0785824 8891.83 2128.20 1579.35 2954.39 6236.98 203.39 130.046225 1118.95 1976.271186 1539.291217
normal	skin 0.1 0 face 761.96 493.39 307.6196474 25172.23 2268.89 3637.28 4189.55 7283.06 1006.30 188.6020151 868.39 1770.780856 1085.012594
normal	skin 0.1 0 face 473.94 916.54 368.9577039 13921.83 1696.37 1408.23 3572.89 5707.70 682.40 159.3655589 1313.07 1545.694864 725.0755287
normal	skin 0.1 0 face 340.51 459.82 269.8149682 11566.14 1643.19 3832.64 3629.94 12653.69 1007.46 228.9422811 714.72 1130.350732 665.5619994
scar 0.1 1 face 11506.15 1012.84 522.7394329 75623.33 4316.75 6423.76 9644.19 14473.52 14425.90 258.4269663 13394.33 9704.654896 4336.543606
Scar 0.1 1 leg 179935.84 9874.77 2300.617957 167178.12 10816.43 9965.47 73685.39 36193.75 92290.80 34655.21628 18085.61 42530.17085 7064.703744
SCC 2 2 leg 12453.49 987.77 277.9516358 78533.43 2409.39 13660.88 10998.29 11006.83 9678.81 1545.376956 8456.90 6017.923186 5272.830725
SCC 1.5 2 head 5136.31 1122.83 376.2033115 45673.85 2946.86 1651.14 3229.50 10458.22 9922.22 180.9780516 10328.07 4017.712745 6355.025029
SCC 3 1 face 31110.54 2689.39 336.4325069 28187.33 896.35 2864.33 9141.87 23636.71 10602.96 1380.853994 4013.43 3047.520661 1948.347107
SCC 2 3 scalp 397593.17 1307.23 392.3694779 228052.21 4112.85 1620.88 62953.41 10557.03 30479.52 9626.907631 4295.18 35718.4739 2691.566265
SCC 3 3 scalp 97423.02 3259.09 1299.358517 163621.53 6718.82 1803.99 16374.55 21993.23 74810.41 1915.894512 3893.80 35170.70563 5537.419815
SCC 1 1 scalp 380441.10 3636.53 1798.630137 456995.43 9098.63 6573.52 33204.57 29348.86 208659.82 7725.570776 30478.54 71974.88584 12222.83105
SCC 1.5 2 face 19146.69 2838.68 509.4076655 348717.77 6966.55 4831.71 10045.99 20769.34 169835.89 605.5749129 5489.90 5924.390244 14456.44599
SCC 1 3 scalp 238.80 274.19 224.5460814 25678.92 233.05 275.57 2428.87 4254.42 5539.42 96.98919789 1407.72 940.7032866 955.8722133
SCC 3 3 leg 237868.09 1083.37 371.4560308 240466.12 3758.77 1622.06 26491.35 23312.59 101476.21 1622.537242 2475.25 3650.408457 9823.882749
SCC 2 3 arm 59242.78 707.52 254.2284673 89112.67 3866.77 1236.79 7196.46 13095.50 9482.96 1252.14676 9549.05 3929.221962 4231.850117
SCC 2 1 face 4082.72 549.07 289.6531278 44827.16 1880.82 5014.53 3737.03 4315.15 9254.37 125.111177 8059.29 3676.845538 3380.670027
SCC 2.6 2 leg 253580.90 2010.73 1097.688498 275404.51 23667.31 20018.44 95812.60 24732.25 366128.23 4274.35333 8877.00 12096.58778 61866.81343
SCC 2 2 face 5271.53 1889.24 999.6527778 100604.86 10191.32 7079.86 10307.29 21324.65 21662.50 1020.486111 24105.21 13328.125 11957.29167
SCC 0.5 3 face 351.26 352.71 352.7075812 352.71 366.06 332.85 352.71 345.13 238.27 152.3465704 3907.58 1477.617329 2780.505415
SCC 0.8 2 face 391616.69 8125.00 6716.376582 395893.99 7365.51 5469.94 26074.76 66369.46 526309.34 6798.259494 7571.60 29943.43354 92584.6519
SCC 5 2 arm 201507.63 17505.19 4893.751272 162412.78 4118.66 2723.39 82519.23 12213.11 112235.70 38809.89212 20440.26 45664.15632 12913.69835
SCC	(IEC	at	the	edge) 4 3 scalp 160894.13 5671.45 1482.240437 341810.11 4554.64 2286.89 22991.80 27062.84 192739.41 1079.918033 10209.70 8146.174863 29997.60929
SCC	in	situ 0.2 1 face 4361.36 2145.92 394.9070331 404535.17 8010.51 5227.16 10012.13 17665.32 71831.85 208.1649151 3274.05 2561.843169 34556.99272
SCC	in	situ 0.2 1 thorax 522.28 850.46 430.9660344 441473.31 5062.64 3275.25 5128.80 7854.43 90735.77 186.1490957 2543.45 2693.868549 14648.43405
SCC	in	situ	 0.8 2 face 650.33 378.98 223.7233799 47725.21 1373.94 803.98 2589.88 2944.36 6765.51 96.63384474 1994.50 2275.704145 1114.266087
SCC	in	situ/AK 1 1 scalp 187182.27 751.18 324.8251087 189226.70 3661.75 2944.03 7131.78 13292.87 115211.95 638.3059179 8444.70 5225.373417 16463.98185
SCC	insitu	&	scar	(re-excision	of	SCC) 1.2 2 scalp 318.21 276.03 195.2828303 48124.33 2071.76 1351.19 3686.39 12563.86 7488.31 405.9564261 3986.81 818.1091345 3433.739756
SCC-Keratocaanthoma 1.2 2 leg 2117.03 614.07 231.4617389 96550.82 1460.79 3201.37 13505.80 10780.62 10470.50 99.97630893 1724.95 2019.189765 2516.939114
SCC(	good	tumour	volume) 6.5 2 scalp 6529.10 2936.92 434.0293203 55689.03 4604.62 2686.81 10069.30 33826.30 12076.85 723.6783652 4113.73 5558.418481 4361.172812
SCC/	Acanthoma 7.5 1 arm 55925.81 1352.90 441.6129032 92251.94 19403.23 3187.74 121968.06 20590.32 18913.55 2141.935484 12898.39 8812.903226 4743.548387
SCC/	Acanthoma 2.5 3 arm 96697.76 5146.22 2144.537815 280341.74 5186.27 3796.36 67122.69 96722.41 372691.88 4217.927171 10465.55 20628.57143 64649.57983
superficial	scar 0.1 1 leg 49.03 47.85 27.99426934 3729.68 289.89 113.64 278.74 405.96 398.54 12.09169054 541.75 246.7908309 351.4040115
Superficial	SCC 1.5 3 face 43000.00 3095.86 345.5960382 76804.03 2215.78 5100.11 7022.64 17832.68 29119.21 1235.939158 5977.36 8342.058719 3130.173329
Superficial	SCC	(Bowens) 0.1 1 thorax 2797.91 235.61 139.9312518 13298.63 145.23 2522.77 2294.61 5653.82 1351.76 60.44113435 675.74 586.221713 526.4967058
Well	Differentiated	SCC 0.8 1 face 36029.37 894.77 407.6823757 42146.55 3888.96 4687.54 27060.04 20933.83 7185.60 1813.105229 8342.48 3103.292447 4216.26856
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 Appendix 2 
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Appendix 3 
 
CONSENT FORM 
 
(THE CYTOKINE MICROENVIRONMENT OF SCCs AND PRECURSOR LESIONS) 
 
1. I, the undersigned .......................................................... hereby consent to  
 my involvement in the above study. 
 
2. The procedure involving the excision and pathological examination of your lesion will proceed as per Dr 
Lewandowski’s regular practice. 
The research will involve: 
 Complete pathological examination of the excised specimen. Any remaining tissue fragments will be 
transferred to the Translational Research Institute at the Princess Alexandra Hospital campus.  
Here, the sample, and the minimal amount of patient information will be processed and prepared for the tests 
required for immune analysis.  
The information collected from this study will contain no identifiable individual patient data. 
 
3. I acknowledge that the nature, purpose and contemplated effects of the study so far as it affects me have been 
fully explained to me by the research worker and my consent is given voluntarily.   I have also read and 
understand the Patient Information Sheet. 
 
4. Although I understand that the purpose of this research project is to improve the quality of medical care, it has 
also been explained that my involvement may not be of any benefit to me. 
 
5. I have been given the opportunity to have a member of my family or a friend present while the study was 
explained to me. 
  
6. I am informed that no information regarding my medical history will be divulged and the  results of any tests 
involving me will not be published so as to reveal my identity.  
 
7. I understand that my involvement in the study will not affect my relationship with my  medical advisers in 
their management of my health.   I also understand that I am free to  withdraw from the study at any stage 
without my future treatment being affected. 
 
8. I understand that where biological material is collected, it may be stored and used for future research purposes 
either with my further consent or (in circumstances where my further consent cannot be obtained or is 
impractical to obtain) with the further specific approval of a hospital ethics committee set up in accordance with 
the NHMRC guidelines”. 
 
9. I give permission for the release of information regarding progress in this study to the study centre, on the 
understanding that while the study centre will keep confidential results under my name, no published study will 
identify me in any way. 
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10. I authorise the Greenslopes Private Hospital to allow access to relevant medical records to the investigators 
from the University of Queensland School of Medicine. 
 
11. I have been told that this study has been approved by the Ethics Committee at Greenslopes Private Hospital. 
 
 
 
 
 Signed .................................................. Date ...................................... 
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Appendix 4 
 
 
 
PATIENT INFORMATION SHEET 
 
THE PURPOSE OF THE STUDY 
• Australia has the highest rate of non-melanoma skin cancer in the world.  The Cancer Council 
Australia's Clinical Guidelines Network estimates that the combined cost of Squamous Cell Carcinoma 
(SCC) and Basal Cell Carcinoma treatment together involves the greatest cost of cancer care in 
Australia, totalling $A345 million per year, with approximately 130,000 new cases of SCC each year.  
While SCC is rarely fatal if treated early, the disease is especially prone to recurrence as a result of 
irreversible sun-damage to the skin, and is particularly prevalent in immunosuppressed transplant 
recipients, who suffer a 10-100 fold increased risk of developing SCC when compared with the 
general population1. Patients endure significant disfigurement, both from the disease and from its 
management.  There is a critical need for more effective prevention and treatment strategies to enable 
oncologists to provide long-lasting protection from tumour formation and/or recurrence. 
• There are many different early stage lesions that can progress to form Squamous Cell Carcinoma. Of 
these, the ‘earliest’ stage is thought to be Actinic (Solar) Keratosis. Unlike late stage or invasive SCC, 
the vast majority of AK lesions in immune eompetent patients eventually regress, with an estimated 1-
10% of AK lesions progressing to invasive SCC.  
• Recent studies have shown that as the immune system can fight off the majority of AKs, there are 
drugs such as Diclofenac and Imiquimod, which can help stimulate the body to eradicate these 
lesions.  
• The role of the immune system is clearly very important in fighting skin cancers, but to date is 
relatively poorly understood.  
• Understanding the role of the immune system will thus help us to better manage early AK lesions, and 
reduce the progression of these early lesions into more invasive and destructive SCCs. 
• Cells of the skin produce specific proteins in small amounts, known as cytokines. These are signalling 
markers that allow cells to communicate with one another. By identifying the cytokine environment 
within lesions from AK to late stage invasive SCC, it is hoped that new and improved approaches for 
the diagnosis of precursor lesions will be developed.  
• It is hoped then, that by understanding the cytokine profile of early and later stage cancers, we may be 
able to predict which lesions will regress through the bodys own immune system, and which lesions 
will progress to more invasive SCC – allowing us to more appropriately treat each type at an earlier 
stage. 
• To do this, the tissue fragments remaining from your excised skin cancer will undergo Flow Cytometry, 
and cytokine-assay to look for the specific immune cells and proteins we are looking for.  
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Your Role: 
• This is a research study looking at excised skin lesions after they have been clinically 
and pathologically examined. 
• Your consent is required to allow research to be conducted on your skin cancer after it 
has been looked at by the pathologist. 
• Your refusal/acceptance to consent in the study will not affect your treatment by any of 
your treating doctors. 
• You will not be identified by any of the information collected, and will not be contacted 
by the study group unless you wish to be. 
• You will be required to fill in an questionnaire relating to your sun exposure, immune 
status and general medical health.  
• If at any time you do not feel comfortable with your tissue being used for research 
purposes, you may withdraw your consent from the study and have your tissue 
removed from use. 
 
• This research is for the completion of a Master of Philosophy project conducted by 
Andrew Lewandowski from the University of Queensland School of Medicine. The 
project will be funded by the University of Queensland Dermatology Research Centre 
and the Translational Research Institute. The researchers will not receive financial 
incentive for their part in the study. 
 
• Dr Lewandowski will be aware of your participation in the project, however as the 
research will not impact on your treatment, there will be no impact on your clinical 
relationship with him or the other doctors involved in your care. 
 
• Your tissue sample and information will be de-identified to protect your privacy once it 
has reached the research facility.  
 
• While the information collected about you and your tissue specimen will be de-
identified, it is important that you are aware that it may be viewed, and used by the 
Greenslopes Hospital Staff as a means of auditing and regulation of studies that are 
conducted on the hospital campus. 
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• You will not be contacted again by the study group at the conclusion of your clinical 
treatment by Dr Lewandowski. If you wish to contact the study group or to receive 
notification of the results and publication of any data that comes as a result of your 
involvement in the study, please contact the Principal Investigator: 
 
• Andrew Lewandowski 
 
• andrew.lewandowski@uqconnect.edu.au  
 
• 0406646695 
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